|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11446246||AZURITY||Suspensions and diluents for metronidazole and baclofen|| |
(13 years from now)
|US11324696||AZURITY||Suspensions and diluents for metronidazole and baclofen|| |
(14 years from now)
Fleqsuvy is owned by Azurity.
Fleqsuvy contains Baclofen.
Fleqsuvy has a total of 2 drug patents out of which 0 drug patents have expired.
Fleqsuvy was authorised for market use on 04 February, 2022.
Fleqsuvy is available in suspension;oral dosage forms.
Fleqsuvy can be used as indicated for the treatment of spasticity resulting from multiple sclerosis.
The generics of Fleqsuvy are possible to be released after 29 September, 2037.
Market Authorisation Date: 04 February, 2022
Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic